TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25176293

Group type: EXPERIMENTAL
Intervention: Incision at 1/2 of the urethral length
Number of subjects: 123

Group type: COMPARATOR
Intervention: Incision at 1/3 of the urethral length
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Incision at 1/2 of the urethral length (subgroup analysis for normal urethral mobility)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Incision at 1/3 of the urethral length (subgroup analysis for normal urethral mobility)
Number of subjects: 123
Study: 22781507

Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention
Number of subjects: 198
Study: 21036512

Group type: EXPERIMENTAL
Intervention: Opioid maintenance medications
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Drug treatment programs
Number of subjects: 946
Study: 18500098

Group type: EXPERIMENTAL
Intervention: LASIK surgery with the WaveLight ALLEGRETTO WAVE Excimer Laser System
Number of subjects: 151
Study: 17006925

Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (UFT) 300 mg/day for 1 year after surgery (n = 79)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Surgery alone (control group, n = 80)
Number of subjects: 160
Study: 14583715

Group type: EXPERIMENTAL
Intervention: 1.5 mL 4% atomized lidocaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.5 mL 4% atomized cocaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 mL 2% lidocaine gel
Number of subjects: 30
Study: 10768306

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) treatment
Number of subjects: 131
Study: 8648924

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nadroparin (DD group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nadroparin (SD group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nadroparin (SD + C group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 21
Study: 1298089

Group type: EXPERIMENTAL
Intervention: Fansimef (125 mg mefloquine + 250 mg sulfadoxine + 12.5 mg pyrimethamine)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Lariam (125 mg mefloquine)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Fansidar (500 mg sulfadoxine + 25 mg pyrimethamine)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Chloroquine (300 mg)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Fansimef
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Lariam
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Fansidar
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 602
Study: 6094449

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 30928620

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (150 mg twice daily and 2 mg once daily respectively)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 870
Study: 29122646

Group type: EXPERIMENTAL
Intervention: Melphalan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study: 26882500

Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counseling program
Number of subjects: 175

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 175
Study: 25090110

Group type: EXPERIMENTAL
Intervention: HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine
Number of subjects: 186
Study: 22733022

Group type: EXPERIMENTAL
Intervention: Bolus flavopiridol (50 mg/m²/day, Arm A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Hybrid flavopiridol (30 mg/m² over 30 min followed by 40 mg/m² over 4 h, Arm B)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Bolus flavopiridol (Arm A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Hybrid flavopiridol (Arm B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 78
Study: 20854987

Group type: EXPERIMENTAL
Intervention: Synbiotic product containing Lactobacillus acidophilus CHO-220 and inulin
Number of subjects: 32
Study: 17588490

Group type: EXPERIMENTAL
Intervention: 12-step-based drug treatment program (Treatment group)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Waiting List group
Number of subjects: 315

Group type: COMPARATOR
Intervention: Community Control group
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 315
Study: 16320747

Group type: EXPERIMENTAL
Intervention: Electroacupuncture and ultrashort‐wave treatment from the acute stage (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ultrashort‐wave treatment at the acute stage and ultrashort‐wave plus electroacupuncture at the resting stage (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Group A)
Number of subjects: 120
Study: 11782652

Group type: EXPERIMENTAL
Intervention: High-fat diet (2.5 g x kg(‐1) x d(‐1) CHO, 4.3 g x kg(‐1) x d(‐1) fat; FAT-adapt)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-carbohydrate diet (9.3 g x kg(‐1) x d(‐1) CHO, 1.1 g x kg(‐1) x d(‐1) fat; HCHO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both interventions (FAT-adapt and HCHO)
Number of subjects: 8
Study: 9718242

Group type: EXPERIMENTAL
Intervention: Health promotion lessons (intervention group, high-risk; IGHR)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (high-risk; CGHR)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Health promotion lessons (HRf-IGHR)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (HRf-CGHR)
Number of subjects: 314
Study: 7853690

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 20 mg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at 40 mg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) in patients with purulent meningitis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cefmetazole, ceftazidime, cefuzonam, flomoxef
Number of subjects: 48
Study: 2582636

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no adenoidectomy)
Number of subjects: 40
Study: 66871

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune serum globulin (antibody titer 1:355,000)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Standard gamma globulin (1:100)
Number of subjects: 243

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 243
Study: 6101354

Group type: EXPERIMENTAL
Intervention: Premarin alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Premarin plus norethisterone acetate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Post-treatment equilin levels in group 1
Number of subjects: 13

Group type: COMPARATOR
Intervention: Post-treatment equilin levels in group 2
Number of subjects: 13
Study: 30964969

Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean Smart with Premium Plaque Control brush head (DCS)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Oral‐B Genius 8000 with FlossAction brush head (OBG)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean Smart (DCS)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Oral‐B Genius 8000 (OBG)
Number of subjects: 219
Study: 27129571

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided bilateral TAP block with 0.5 mL/kg of 0.25% bupivacaine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group received saline instead of bupivacaine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 27345639

Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy (21 Gy in three fractions within 42 days of the pleural intervention)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Deferred radiotherapy (same dose given within 35 days of PTM diagnosis)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Deferred radiotherapy
Number of subjects: 203
Study: 24576799

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 830

Group type: COMPARATOR
Intervention: Restricted approach (using clinical criteria to determine escalation of support)
Number of subjects: 830
Study: 22008454

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus calorie restriction (AEX + CR)
Number of subjects: 96
Study: 19145644

Group type: EXPERIMENTAL
Intervention: Combat exposure
Number of subjects: 2820

Group type: EXPERIMENTAL
Intervention: Group cohesion
Number of subjects: 2820

Group type: COMPARATOR
Intervention: Baseline psychological symptoms
Number of subjects: 2820
Study: 17595785

Group type: EXPERIMENTAL
Intervention: High serum IGF-1 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum IGF-1 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IGF-1 expression in breast cancer tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identifying IGF-1 gene polymorphism
Number of subjects: 0
Study: 15196523

Group type: EXPERIMENTAL
Intervention: VmaxST system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Douglas Bag method
Number of subjects: 10
Study: 11222470

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg TID (n=20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n=19)
Number of subjects: 39
Study: 9893547

Group type: EXPERIMENTAL
Intervention: Pethidine 5 mg.ml‐1 with adrenaline 5 micrograms.ml‐1 (adrenaline group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Pethidine 5 mg.ml‐1 without adrenaline (plain group)
Number of subjects: 78
Study: 7986965

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.d. for 6 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo b.d. for 6 days
Number of subjects: 12
Study: 2735519

Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.5 mg terbutaline sulphate)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metered Dose Inhaler (MDI) (0.5 mg terbutaline sulphate)
Number of subjects: 19
Study: 1038622

Group type: EXPERIMENTAL
Intervention: Decoded auditory information
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Coded auditory information
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ambient auditory information
Number of subjects: 180
Study: 31200823

Group type: EXPERIMENTAL
Intervention: Combination group (icotinib plus pemetrexed and carboplatin)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Icotinib only group
Number of subjects: 179
Study: 27865015

Group type: COMPARATOR
Intervention: Any cannabis use during treatment
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Second quartile of cannabis use (1-2 days per month)
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Any cannabis use or quartiles of cannabis use
Number of subjects: 1383
Study: 25464828

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS) combined with F‐MP (motor practice inducing learning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS) combined with S‐MP (motor practice not inducing learning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulation (Ctrl) combined with F‐MP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulation (Ctrl) combined with S‐MP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor evoked potentials (MEPs) recorded before and after motor practice (TMS‐pre and TMS‐post)
Number of subjects: 0
Study: 23644079

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg ∙ kg(‐1) ∙ day(‐1))
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional management (immunosuppressant therapy only if corticosteroid dependency, chronic active disease, poor response to corticosteroids, or severe perianal disease)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 132
Study: 21078826

Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered every 2 weeks for 2 months on and 2 months off (arm A)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Continuous chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered continuously (arm B)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (arm A)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Continuous chemotherapy (arm B)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Second-line oxaliplatin-based treatment
Number of subjects: 337
Study: 19402741

Group type: EXPERIMENTAL
Intervention: Physical activity guidelines with varying frequency, intensity, duration, and mode
Number of subjects: 27

Group type: COMPARATOR
Intervention: Factors unrelated to recommended guidelines
Number of subjects: 27
Study: 17302722

Group type: EXPERIMENTAL
Intervention: Unipolar, single site pacing with AF algorithm ON
Number of subjects: 72

Group type: COMPARATOR
Intervention: Unipolar, single site pacing with AF algorithm OFF
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Bipolar, dual-site pacing with AF algorithm ON
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bipolar, dual-site pacing with AF algorithm OFF
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AF prevention algorithm ON
Number of subjects: 72
Study: 15001789

Group type: EXPERIMENTAL
Intervention: Daily additional sensorimotor stimulation of the arm for 6 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no additional stimulation)
Number of subjects: 100
Study: 10744088

Group type: EXPERIMENTAL
Intervention: 1 mg alosetron orally twice daily for 12 weeks
Number of subjects: 647

Group type: COMPARATOR
Intervention: Placebo orally twice daily for 12 weeks
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: 1 mg alosetron
Number of subjects: 647

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study: 8759064

Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg daily)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 1349031

Group type: EXPERIMENTAL
Intervention: Interferon-alpha, 1.25-7.5 x 10(6) units/m2 subcutaneously three times/week
Number of subjects: 13
Study: 4006661

Group type: EXPERIMENTAL
Intervention: Professional instruction by a diabetes educator for 30 minutes
Number of subjects: 2

Group type: COMPARATOR
Intervention: Self-instruction using written package instructions for 30 minutes
Number of subjects: 2
Study: 30995176

Group type: EXPERIMENTAL
Intervention: Idelalisib (IDELA) 150 mg twice daily plus rituximab
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 110
Study: 27889290

Group type: EXPERIMENTAL
Intervention: Topical broccoli sprout extract (BSE) (500 nmol of sulforaphane/mL)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 5
Study: 25424047

Group type: EXPERIMENTAL
Intervention: Apitherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23287903

Group type: EXPERIMENTAL
Intervention: Cell saver transfusion
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (crystalloid or albumin for volume replacement and RBCs for anemia)
Number of subjects: 106
Study: 21198375

Group type: EXPERIMENTAL
Intervention: Standard laparoscopic donor nephrectomy (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site donor nephrectomy (group B)
Number of subjects: 50
Study: 17638004

Group type: EXPERIMENTAL
Intervention: Patching plus oral CDP‐choline (800 or 1,200 mg based on body weight) for 30 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Patching alone for 30 days
Number of subjects: 61
Study: 16889731

Group type: EXPERIMENTAL
Intervention: Percutaneous reduction and fixation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 37
Study: 14570678

Group type: EXPERIMENTAL
Intervention: Group US (ultrasound-guided supraclavicular block)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group NS (anatomical landmarks supraclavicular block)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group US
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group NS
Number of subjects: 80
Study: 10340903

Group type: EXPERIMENTAL
Intervention: Four cycles of bleomycin‐etoposide‐cisplatin followed by two cycles of etoposide‐cisplatin with or without filgrastim
Number of subjects: 380

Group type: COMPARATOR
Intervention: Three cycles of bleomycin‐vincristine‐cisplatin followed by three cycles of etoposide‐ifosfamide‐cisplatin‐bleomycin with or without filgrastim
Number of subjects: 380
Study: 7574020

Group type: EXPERIMENTAL
Intervention: 6% hetastarch plus 1 L lactated Ringer's solution (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (n = 20)
Number of subjects: 40
Study: 1662879

Group type: EXPERIMENTAL
Intervention: Oral temafloxacin (600 mg b.i.d.)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Oral cefadroxil (500 mg b.i.d.)
Number of subjects: 374
Study: 6128492

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 768

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 768
Study: 31706460

Group type: EXPERIMENTAL
Intervention: Abriendo Caminos Program (6 weekly, 2-hour group workshops on nutrition education, family wellness, and physical activity)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Abbreviated-attention control group
Number of subjects: 500
Study: 27569864

Group type: EXPERIMENTAL
Intervention: INDIVIDUO intervention group (IG)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 94
Study: 25733636

Group type: EXPERIMENTAL
Intervention: Favorite food (measured by Food Pmax) vs Baby Einstein-Baby MacDonald shows (study 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Favorite food (measured by Food Pmax) vs bubbles (study 2)
Number of subjects: 57
Study: 24323139

Group type: EXPERIMENTAL
Intervention: Housing First (independent apartments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Housing First (congregate residence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 22688849

Group type: EXPERIMENTAL
Intervention: Peginterferon/ribavirin lead-in therapy
Number of subjects: 834

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 834
Study: 19223704

Group type: EXPERIMENTAL
Intervention: Active surgical treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 49
Study: 17215033

Group type: EXPERIMENTAL
Intervention: Codfish digested at pH 2.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codfish digested at pH 3.0
Number of subjects: 0

Group type: COMPARATOR
Intervention: Undigested codfish extracts
Number of subjects: 0
Study: 15902303

Group type: EXPERIMENTAL
Intervention: UM‐CLL B cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M‐CLL B cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutated nonautoreactive CLL antibody sequences reverted to germline counterparts
Number of subjects: 0
Study: 12581508

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium aerosol (4 mg) inhaled 30 minutes before allergen challenge
Number of subjects: 10
Study: 9497185

Group type: EXPERIMENTAL
Intervention: lactoovovegetarian diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: nonvegetarian diet
Number of subjects: 21
Study: 9873197

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of GH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined continuous infusion and bolus injections of GH
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bolus injections of GH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous (s.c.) infusion of GH
Number of subjects: 23

Group type: COMPARATOR
Intervention: Daily s.c. injections of GH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Continuous GH pattern
Number of subjects: 23
Study: 1914718

Group type: EXPERIMENTAL
Intervention: SCFA irrigation (acetate: 60 mmol/liter; propionate: 30 mmol/liter; N-butyrate: 40 mmol/liter)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Isotonic NaCl
Number of subjects: 13
Study: 6356898

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg (single dose and three times a day for three days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Labetalol 300 mg (single dose and twice a day for three days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg three times a day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Labetalol 300 mg twice a day
Number of subjects: 11
Study: 29608340

Group type: EXPERIMENTAL
Intervention: Exercise intervention (4 weekly 1-hour group-based exercise classes targeting strength training, endurance, balance, and flexibility)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Attribution retraining session (1-hour session teaching that aging does not mean one inevitably becomes sedentary)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Control group (generic health education)
Number of subjects: 572
Study: 30205379

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day plus PTX (400 mg b.i.d.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Escitalopram 20 mg/day plus placebo
Number of subjects: 80
Study: 25823668

Group type: EXPERIMENTAL
Intervention: RG7652 400 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RG7652 800 mg every 8 weeks
Number of subjects: 0
Study: 23298410

Group type: EXPERIMENTAL
Intervention: SOC plus Dermagraft® (bioengineered ECM containing living fibroblasts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SOC plus Oasis® (ECM devoid of living cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study: 21450063

Group type: EXPERIMENTAL
Intervention: Combined implementation (CI) strategy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual educational (ED) strategy
Number of subjects: 45